Under the terms of the agreement, PerkinElmer will provide instrumentation, reagents and screening expertise that will help the Ministry of Health screen for congenital hypothyroidism and triple its screening capacity.
Through this agreement, the Mexican Ministry of Health will use PerkinElmer’s Delfia and AutoDelfia neonatal thyroid-stimulating hormone kits, and Victor platform to screen for congenital hypothyroidism in newborns.
Robert Friel, president and CEO of PerkinElmer, said: “PerkinElmer is the world’s leading supplier of newborn screening systems and remains committed to supporting the expansion and standardization of newborn screening programs worldwide with leading technology to allow for early detection of potentially life-threatening disorders.”